Zhou Kun, Zhang Shui-Shen, Yan Yan, Zhao Song
Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
Med Oncol. 2014 Jul;31(7):17. doi: 10.1007/s12032-014-0017-5. Epub 2014 May 31.
Transient receptor potential vanilloid 2 (TRPV2) was proved to play a crucial role in the tumor progression of various cancers. The association between the expression of TRPV2 and clinical outcome in cancer patients has not been studied yet. We aim to elucidate the role of TRPV2 in predicting prognosis of patients with esophageal squamous cell carcinoma (ESCC). Fresh frozen samples were collected immediately from 170 patients with ESCC after surgical resection from 2003 to 2008, including 45 pairs of tumor tissues and non-tumor tissues. TRPV2 expression was measured by quantitative real-time PCR. TRPV2 mRNA was over-expressed in ESCC tissues and cell lines. High expression of TRPV2 was observed more frequently in patients with advanced pT stage (P < 0.001), lymph node metastasis (P = 0.010) and advanced pathological stage (P = 0.001). Patients with high expression of TRPV2 (>44.40, n = 83) had worse 5-year disease-specific survival (40.0 vs 62.6 %, P < 0.001) and disease-free survival (38.4 vs 61.5 %, P < 0.001) than that with low expression (≤ 44.40, n = 87). Multivariate analysis found that the expression of TRPV2 mRNA (HR 2.19, 95 % CI 1.39-3.46, P = 0.031) and pN category (HR 2.13, 95 % CI 1.36-3.33, P = 0.001) were independent prognostic factors. Overexpression of TRPV2 mRNA was associated with poor prognosis and might serve as a novel prognostic biomarker for resected ESCC patients in early stage.
瞬时受体电位香草酸亚型2（TRPV2）已被证明在多种癌症的肿瘤进展中起关键作用。TRPV2表达与癌症患者临床结局之间的关联尚未得到研究。我们旨在阐明TRPV2在预测食管鳞状细胞癌（ESCC）患者预后中的作用。2003年至2008年，对170例接受手术切除的ESCC患者立即采集新鲜冷冻样本，其中包括45对肿瘤组织和非肿瘤组织。通过定量实时PCR检测TRPV2表达。TRPV2 mRNA在ESCC组织和细胞系中过表达。在pT分期较晚（P < 0.001）、有淋巴结转移（P = 0.010）和病理分期较晚（P = 0.001）的患者中，更频繁地观察到TRPV2高表达。TRPV2高表达（>44.40，n = 83）的患者5年疾病特异性生存率（40.0%对62.6%，P < 0.001）和无病生存率（38.4%对61.5%，P < 0.001）低于低表达（≤ 44.40，n = 87）的患者。多因素分析发现，TRPV2 mRNA表达（HR 2.19，95%CI 1.39 - 3.46，P = 0.031）和pN分类（HR 2.13，95%CI 1.36 - 3.33，P = 0.001）是独立的预后因素。TRPV2 mRNA过表达与预后不良相关，可能作为早期切除的ESCC患者的一种新型预后生物标志物。
